Kleo Pharmaceuticals

33 articles about Kleo Pharmaceuticals

• Kleo Pharmaceuticals Presents Preclinical Data on KPMW135, a Novel CD3 x CD20 Bispecific Version of Rituximab

  12/7/2020

  Kleo Pharmaceuticals, Inc. , a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, is presenting preclinical data today on KPMW135, a novel CD3 x CD20 bispecific molecule developed with Kleo’s multi-targeted antibody therapy enhancer (MATE™) conjugation platform.

• Kleo Pharmaceuticals Announces Data Presentation on KPMW135, a Novel CD3 x CD20 Bispecific Molecule, and Conjugation Platform (MATE™) at The 62nd Annual Society of Hematology (ASH) Meeting

  11/30/2020

  Kleo Pharmaceuticals, Inc., a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, announced that it will present data on KPMW135, a novel CD3 x CD20 bispecific molecule, created by chemically conjugating a CD3- binder directly to rituximab (Rituxan®) using its multi-targeted antibody therapy enhancer (MATE) platform.

• Kleo Pharmaceuticals Presents Preclinical Proof-of-Concept Data on a Novel Chemical Conjugation Platform (MATE™) at the Society for Immunotherapy of Cancer's (SITC) 35th Annual Meeting

  11/9/2020

  Kleo Pharmaceuticals, Inc., a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, announced the presentation of proof-of-concept data on KPMW101, an anti-tumor therapeutic agent created with the company’s multi-targeted antibody therapy enhancer conjugation platform.

• Kleo Pharmaceuticals Announces Data Presentation on Novel Conjugation Platform at the Society for Immunotherapy of Cancer's (SITC) 35th Annual Meeting

  10/29/2020

  Kleo Pharmaceuticals, Inc. , a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, announced that it will present data from its multi-targeted antibody therapy enhancer (MATE™) conjugation platform at the upcoming Society for Immunotherapy of Cancer's (SITC) 35 th Annual Meeting. The meeting is taking place in a virtual format from November 9-14, 2020. Details of the p

• Kleo Pharmaceuticals to Present at “Bioscience Pipeline & Innovation in Connecticut in the Age of COVID” Conference

  9/21/2020

  Kleo Pharmaceuticals, Inc., a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, announced that it will present today to local stakeholders at the Bioscience Pipeline & Innovation in Connecticut in the Age of COVID conference on Monday, September 21, 2020 at 2:00 p.m. ET

• Kleo Pharmaceuticals Announces Orphan Drug Designation for KP1237 in Multiple MyelomaCD38-Targeting Molecule To be Evaluated in Multiple Patient Populations

  9/8/2020

  Kleo Pharmaceuticals, a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, announced today that its lead compound, KP1237, has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) in multiple myeloma. KP1237 is an antibody-redirecting molecule (ARMä) that targets CD38, a clinically validated target for multiple myeloma. “We are pleased to r

• Kleo Pharmaceuticals to Present at the LifeSci Partners Summer Symposium

  7/29/2020

  Kleo Pharmaceuticals announced today that Doug Manion, MD, Chief Executive Officer and Chairman of the Board, will be presenting a corporate overview at the Private Healthcare Company Virtual Summer Symposium, hosted by LifeSci Partners on August 4 and 5, 2020. Please click the following link to register: https://lifesci.events/SummerSymposium . Presentation Details: Date: August 5, 2020 Time: 8:30am Eastern Time About Kl

• Kleo Pharmaceuticals Announces $5 Million Grant to Advance Development of COVID-19 Hyperimmune Globulin Mimic (HGM) as a Therapeutic for Infected Patients

  7/8/2020

  The Grant from the Bill & Melinda Gates Foundation Accelerates Company’s Efforts to Enter Clinical Trials by Early 2021

• Kleo Pharmaceuticals to Present Corporate Overview and Pipeline Update at Jefferies Virtual Healthcare Conference

  6/1/2020

  Kleo Pharmaceuticals, Inc., a leading company in the field of developing next-generation, fully synthetic bispecific compounds designed to emulate or enhance the activity of biologics, announced that it will present at the Jefferies Virtual Healthcare Conference 2020 on Thursday, June 4, 2020 at 4:00 p.m. ET.

• Kleo Pharmaceuticals and Celularity Enter into Research Collaboration to Rapidly Develop Allogeneic NK Cell Combination Therapies for COVID-19 and Multiple Myeloma

  5/21/2020

  Synergistic Potential of Kleo’s Antibody Recruiting Molecule (ARM™) and Celularity’s Placental-Derived NK Cells to Be Evaluated in the Context of COVID-19 and Multiple Myeloma

• Kleo Pharmaceuticals to Present Preclinical Data Highlighting the Synergistic Potential of Kleo Asset KP1237 and Autologous NK Cells in the Treatment of Multiple Myeloma at the 2020 American Society of Clinical Oncology Virtual Meeting

  5/15/2020

  Data support the initiation of an upcoming first-in-human trial for first-line, MRD+ multiple myeloma patients post-ASCT

• Kleo Pharmaceuticals Enters into Research Collaboration with Green Cross LabCell (GCLC) To Rapidly Develop COVID-19-Targeting Allogeneic NK Cell Combination Therapy

  3/31/2020

  Kleo Pharmaceuticals Inc announced today that it has entered into a research collaboration with South Korea -based Green Cross LabCell (GCLC),

• Kleo Pharmaceuticals Elects CEO Doug Manion, MD, FCRP (C), New Chairman of the Board

  2/14/2020

  Kleo Pharmaceuticals, Inc., an immuno-oncology company developing next-generation, fully synthetic bispecific compounds designed to emulate or enhance the activity of biologics, announced today the appointment of CEO Doug Manion, MD, FCRP (C), to Chairman of the Board

• Kleo Pharmaceuticals Receives IND Authorization to Proceed from FDA for its Multiple Myeloma Therapeutic

  2/6/2020

  KP1237, a CD38-Targeting Antibody Recruiting Molecule (ARM™), to Be Tested in Combination with NK Cells to Treat Post-Transplant Multiple Myeloma Patients

• Kleo Pharmaceuticals to Present at Biotech Showcase 2020

  12/18/2019

  Kleo Pharmaceuticals, Inc. announced that its Chief Executive Officer Doug Manion, MD, will present at Biotech Showcase 2020, to be held January 13-15, 2020 at the Hilton San Francisco Union Square in San Francisco.

• Kleo Pharmaceuticals to Present at Piper Jaffray 31st Annual Healthcare Conference

  12/2/2019

  Kleo Pharmaceuticals, Inc., an immuno-oncology company developing next-generation, fully synthetic bispecific compounds designed to emulate or enhance the activity of biologics, announced today that its Chief Executive Officer Doug Manion, MD, will present at the Piper Jaffray 31st Annual Healthcare Conference,

• Kleo Pharmaceuticals Presents Preclinical Data Supporting Development of its CD38-ARM™, a Novel Immuno-therapeutic, at American Society of Hematology (ASH) Annual Meeting

  11/6/2019

  Company's Antibody Recruiting Molecules (ARMs) Demonstrated Strong Anti-Multiple Myeloma Activity In Multiple In Vivo Animal Models and Ex Vivo Against Patient Tumor Cells

• Kleo Pharmaceuticals Appoints Thomas J. Lynch, Jr., MD, as Chairman of the Board

  11/4/2019

  Kleo Pharmaceuticals, Inc., a unique immuno-oncology company developing next-generation synthetic bispecific compounds designed to emulate or enhance the activity of biologics, announced today that Thomas J. Lynch, Jr., MD, the former Chief Scientific Officer (CSO) of Bristol-Myers Squibb Company (BMS), joined Kleo's Board of Directors as Chairman effective November 1, 2019.

• Kleo Pharmaceuticals to Present at 2019 BIO Investor Forum

  10/15/2019

  Kleo Pharmaceuticals Inc. announced that its CEO Doug Manion, M.D., FRCP, will present at the 2019 BIO Investor Forum, which will be held at the Westin St. Francis Union Square in San Francisco on October 22-23rd.

• Kleo Pharmaceuticals Announces Open-House Event To Celebrate Innovator of the Month Award

  8/8/2019

  Innovator of the Month award from Senator Chris Murphy (D-Conn.) at an open house event held on August 7, 2019 at the company's newly expanded offices in New Haven, Conn.